Research has shown that prophylactic or therapeutic administration of P2Y13-R, also known as IL-33 and High-mobility group box1 (HMGB1)’s novel gatekeeper, in experimental asthma models can attenuate the onset and progression of asthma (63). Here, IL33 is linked to asthma.